ArticleFrontiers in immunology2025
Accelerated biological aging as a potential mediator mediates the relationship between metabolic syndrome and the risk of psoriasis: a prospective analysis from the UK biobank.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Increasing evidence suggests that metabolic syndrome (MetS) may contribute to the development of psoriasis. However, the mediating role of accelerated aging in this association remains unclear. Methods: This study utilized data from 319,263 participants in the UK Biobank. Cox proportional hazards models were used to assess the associations between MetS, genetic predisposition, and psoriasis risk. Mediation analysis examined the role of accelerated aging (PhenoAgeAccel) in the relationship between MetS, its components, and psoriasis. Results: MetS was associated with a 30% increased risk of psoriasis (HR: 1.30; 95% CI: 1.20-1.40). Among its components, abdominal obesity, low HDL cholesterol, high triglycerides, and hyperglycemia were each independently linked to higher risk. Individuals with both MetS and high genetic susceptibility had a substantially increased risk (HR: 2.93; 95% CI: 2.51-3.43). PhenoAgeAccel significantly mediated 28.8% of the MetS-psoriasis association. Conclusions: MetS and its components play a key role in psoriasis development, especially in genetically susceptible individuals. Accelerated aging may partially explain this link, suggesting a potential biological pathway and underscoring the importance of early MetS identification.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.